CEREVEL THERAPEUTICS HOLDINGS INC. - COMMON STOCK

Cerevel Therapeutics Announces Publication in The Lancet of Emraclidine Data from Phase 1b Clinical Trial in People Living with Schizophrenia

15 Dec 2022 17:30:00 By Nasdaq GlobeNewswire

Cerevel Therapeutics to Present at Upcoming Investor Conferences

11 Nov 2022 05:30:00 By Nasdaq GlobeNewswire

Cerevel Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates

08 Nov 2022 05:30:00 By Nasdaq GlobeNewswire

Cerevel Therapeutics to Report Third Quarter 2022 Financial Results and Pipeline Update on Tuesday, November 8, 2022

19 Oct 2022 05:30:00 By Nasdaq GlobeNewswire

Cerevel Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference

06 Sep 2022 05:30:00 By Nasdaq GlobeNewswire

Cerevel Therapeutics Announces Pricing of $300 Million Private Offering of Convertible Senior Notes and Concurrent $254 Million Public Offering of Common Stock

12 Aug 2022 05:00:00 By Nasdaq GlobeNewswire

Cerevel Therapeutics Announces Pricing of $254 Million Public Offering of Common Stock and Concurrent $300 Million Private Offering of Convertible Senior Notes

12 Aug 2022 05:00:00 By Nasdaq GlobeNewswire

Cerevel Therapeutics Announces Proposed Public Offering of Common Stock

10 Aug 2022 15:01:00 By Nasdaq GlobeNewswire

Cerevel Therapeutics Announces Proposed Private Offering of Convertible Senior Notes

10 Aug 2022 15:01:00 By Nasdaq GlobeNewswire

Cerevel Therapeutics to Report Second Quarter 2022 Financial Results and Pipeline Update on Monday, August 1, 2022

25 Jul 2022 16:00:00 By Nasdaq GlobeNewswire

Cerevel Therapeutics Announces Updates to its Board of Directors

15 Jun 2022 05:30:00 By Nasdaq GlobeNewswire

Cerevel Therapeutics to Present at the Jefferies Healthcare Conference

25 May 2022 05:30:00 By Nasdaq GlobeNewswire

Cerevel Therapeutics Reports First Quarter 2022 Financial Results and Business Updates

10 May 2022 05:30:00 By Nasdaq GlobeNewswire

Cerevel Therapeutics to Report First Quarter 2022 Financial Results and Pipeline Update on Tuesday, May 10, 2022

13 Apr 2022 05:30:00 By Nasdaq GlobeNewswire

Cerevel Therapeutics Announces Upcoming Presentations at AAN 2022

31 Mar 2022 05:30:00 By Nasdaq GlobeNewswire

Cerevel Therapeutics to Present at the Stifel 4th Annual CNS Day Event

21 Mar 2022 05:30:00 By Nasdaq GlobeNewswire

Cerevel Therapeutics Provides Update on Pipeline Progress along with Fourth Quarter and Full Year 2021 Financial Results

01 Mar 2022 05:30:00 By Nasdaq GlobeNewswire

Cerevel Therapeutics to Report Fourth Quarter 2021 Financial Results and Pipeline Update on Tuesday, March 1, 2022

16 Feb 2022 05:30:00 By Nasdaq GlobeNewswire

Cerevel Therapeutics Announces Positive Topline Results for Darigabat in Phase 1 Clinical Trial in Acute Anxiety

15 Feb 2022 05:30:00 By Nasdaq GlobeNewswire

Cerevel Therapeutics to Present at 40th Annual JP Morgan Healthcare Conference: Additional Details of Phase 2 Program for Emraclidine (CVL-231) in Schizophrenia to be Presented

10 Jan 2022 05:30:00 By Nasdaq GlobeNewswire